2019
DOI: 10.1038/s41419-019-1676-0
|View full text |Cite
|
Sign up to set email alerts
|

Arsenic trioxide inhibits liver cancer stem cells and metastasis by targeting SRF/MCM7 complex

Abstract: Hepatocellular carcinoma (HCC) has a high mortality rate due to the lack of effective treatments and drugs. Arsenic trioxide (ATO), which has been proved to successfully treat acute promyelocytic leukemia (APL), was recently reported to show therapeutic potential in solid tumors including HCC. However, its anticancer mechanisms in HCC still need further investigation. In this study, we demonstrated that ATO inhibits tumorigenesis and distant metastasis in mouse models, corresponding with a prolonged mice survi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
43
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
9

Relationship

2
7

Authors

Journals

citations
Cited by 57 publications
(45 citation statements)
references
References 45 publications
2
43
0
Order By: Relevance
“…This agent reduces growth and proliferation of cancer cells by enhancing ROS generation and induction of apoptotic cell death (Emadi & Gore, 2010). ATO is able to diminish migration and invasion of liver cancer cells and also, to inhibit its recurrence by eradication of cancer stem cells via down‐regulation of MCM7 (Wang et al, 2019). ATO reduces oxygen and nutrient supplies of lung cancer cells to inhibit their growth and proliferation.…”
Section: Cryptotanshinone In Cancer Therapymentioning
confidence: 99%
“…This agent reduces growth and proliferation of cancer cells by enhancing ROS generation and induction of apoptotic cell death (Emadi & Gore, 2010). ATO is able to diminish migration and invasion of liver cancer cells and also, to inhibit its recurrence by eradication of cancer stem cells via down‐regulation of MCM7 (Wang et al, 2019). ATO reduces oxygen and nutrient supplies of lung cancer cells to inhibit their growth and proliferation.…”
Section: Cryptotanshinone In Cancer Therapymentioning
confidence: 99%
“…Our results suggested ATO induced cyclin D1 degradation has a similar effect to CDK4/6 inhibitors, caused inhibition of CDK4/6 signaling, induced cancer cell senescence, and inhibited SCC outgrowth in 4NQO induced OSCC and ESCC mouse models in vivo. Additionally, the present study does not preclude some other molecular targets of ATO may also take part in the synthetic effects of co-administration of ATO with checkpoint inhibitor [45]. Collectively, our results offered the first preclinical evidences and molecular mechanisms of combinatory usages of ATO and immune checkpoint inhibitors with synthetic effects for cancer treatment that warrant future clinical studies.…”
Section: Discussionmentioning
confidence: 72%
“…Further, of the seven MCM complex proteins common in all three datasets (HCC, HBV-transfection, and IFN), six were downregulated in the HBV-transfection condition. Targeting of MCM complex proteins has indeed shown promise in combatting liver cancer, 71 prostate cancer, 72 and breast cancer. 73 Other proteins within the 14 member set also figure prominently in cancer research.…”
Section: Resultsmentioning
confidence: 99%